What is the difference between AOD-9604 and Follistatin 344?

AOD-9604: AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. Follistatin 344: Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Is Follistatin 344 FDA approved?

Follistatin 344 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is AOD-9604 administered in research settings?

In research settings, AOD-9604 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is Follistatin 344 administered in research settings?

In research settings, Follistatin 344 is typically administered via the intramuscular route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›AOD-9604 vs Follistatin 344

Peptide Comparison

AOD-9604 vs Follistatin 344

Name: AOD-9604 vs Follistatin 344 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

AOD-9604

Advanced Obesity Drug 9604

Fat LossResearch Only

Half-life: 30–60 minutes

197 providers listed

Full AOD-9604 profile →

Follistatin 344

FST-344

PerformanceNot EvaluatedResearch Only

Half-life: ~24-36 hours

15 providers listed

Full Follistatin 344 profile →

Bottom line

AOD-9604 and Follistatin 344 target different goals — AOD-9604 for selective fat tissue lipolysis via GH C-terminal fragment mechanism, Follistatin 344 for myostatin and activin A neutralization — dual TGF-β inhibition. They're compared here for reference, not as direct substitutes.

Quick Verdict

AOD-9604

Half-life

30–60 minutes

Follistatin 344

Half-life

~24-36 hours

Different Goals

AOD-9604 and Follistatin 344 target different goals — AOD-9604 for GH / IGF Axis, Follistatin 344 for Muscle & Myostatin. They're compared here for reference; there isn't a single “better” choice between them.

Side-by-Side Comparison

AOD-9604

Follistatin 344

Mechanism Family

GH / IGF Axis

Muscle & Myostatin

Half-life

30–60 minutes

~24-36 hours

FDA Status

nomination withdrawn

not evaluated

Admin Routes

subcutaneous, oral

intramuscular

Availability

Research Only

Providers

197 listed

15 listed

Avail. Notes

HGH fragment 176-191. Drug development terminated 2007 (Phase 3 failure). FDA GRAS notice GRN 000792 for food ingredient use only — not a drug approval. No active NDA. Research chemical.

Myostatin inhibitor. No FDA approval. Gene therapy forms in early trials but recombinant protein is a research chemical. WADA prohibited. No NDA or IND for peptide form.

Research Evidence

AOD-9604

Animal · 1 key study · dated evidence base — most recent 2001

Follistatin 344

No citations on file

Research Citations

AOD-9604

Animal2001 · Endocrinology

The effect of the growth hormone fragment AOD9604 on adipose tissue

Follistatin 344

No citations on file.

About AOD-9604

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

Research Areas

selective fat tissue lipolysis via GH C-terminal fragment mechanismadipose metabolism stimulation without IGF-1 elevationoriginally developed to isolate GH lipolytic effect from growth effectssubcutaneous injection — reconstitution with bacteriostatic water required

About Follistatin 344

Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Research Areas

myostatin and activin A neutralization — dual TGF-β inhibitionskeletal muscle hypertrophy in transgenic animal modelssatellite cell activation and muscle protein synthesis reliefgene therapy context: Becker MD phase 1/2a trial safety established

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

AOD-9604

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Follistatin 344

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

AOD-9604

$9.00/mg

$7.71 – $11.85 range

45 vendors

View price index →Find providers →

Follistatin 344

$102.67/mg

$90.00 – $139.00 range

12 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

AOD-9604

197 listed

Browse directory →

Providers offering

Follistatin 344

15 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

Related Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). AOD-9604 vs Follistatin 344 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/aod-9604/follistatin-344

https://peptidebase.io/peptides/compare/aod-9604/follistatin-344 Methodology License Download JSON Download CSV